VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
0.596
+0.001 (0.18%)
At close: Mar 9, 2026, 4:00 PM EDT
0.590
-0.006 (-1.01%)
After-hours: Mar 9, 2026, 4:00 PM EDT
VYNE Therapeutics Employees
VYNE Therapeutics had 13 employees as of December 31, 2024. The number of employees increased by 3 or 30.00% compared to the previous year.
Employees
13
Change (1Y)
3
Growth (1Y)
30.00%
Revenue / Employee
$43,846
Profits / Employee
-$2,037,154
Market Cap
19.87M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Citius Pharmaceuticals | 23 |
| Reviva Pharmaceuticals Holdings | 14 |
| Genenta Science | 13 |
| Allarity Therapeutics | 7 |
| Intensity Therapeutics | 7 |
| Lexaria Bioscience | 7 |
| NanoViricides | 7 |
| Cadrenal Therapeutics | 4 |
VYNE News
- 2 months ago - VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript - Seeking Alpha
- 2 months ago - VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement - GlobeNewsWire
- 4 months ago - VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo - GlobeNewsWire
- 8 months ago - VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - GlobeNewsWire
- 10 months ago - VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 11 months ago - FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - Benzinga